Defra: Disease Outbreaks

Lord Plumb Excerpts

Thursday 27th January 2011 Lords Chamber

[Lord Henley]

My Lords, I am grateful to the noble Countess for reminding us that it is only 10 years since the last major outbreak of foot and mouth, which she, I and many others remember well. I am also grateful to her for mentioning Exercise Silver Birch, which has recently concluded. It was a fairly major exercise organised by Defra, the devolved Administrations and many others, in which more than 600 people took part to look at how a foot and mouth outbreak might affect England, Scotland and Wales. The important thing to remember about it is that it will report in due course. I hope that lessons can be learnt from the report when it is published in, we hope, March of this year. That will probably be when I can comment in more detail on the further points that the noble Countess made, which are very valid at this stage.

[Lord Plumb]

Does the Minister agree that contingency planning and funding are becoming more important, as exotic diseases will probably come into this country through greater globalisation and climate change? Does he accept that, in the ongoing situation, there should be more contingency planning to deal with outbreaks of TB? We are still losing something like 100 cattle a day through tuberculosis. I accept that much is being done, but is Defra satisfied with the efficacy of the vaccine for badgers?

[Lord Henley]

My Lords, my noble friend is right to point to the importance of contingency planning, rather than contingency funding. The important thing is that we plan for these situations. I can give an assurance that Defra has planned and will continue to plan and test for all diseases. I also underline his point about the increasing risk of exotic diseases, which is one possible consequence of climate change. As regards his specific question about the efficacy of the badger vaccine, I can give an assurance that laboratory studies have demonstrated that the vaccination of badgers by injection with BCG significantly reduces the progression, severity and excretion of TB infection after experimental challenge. However, we still have a little way to go on these matters before we can make such vaccines more widely available.